of secondary endpoints (p<0.05). Based on these results, Pfizer has
taken the decision not to launch a global phase 3 development program
for PF-03187207, although Pfizer has indicated that it would consider
continuing the development of PF-03187207 for potential registration in
Asia, including Japan, depending on the results of the ongoing Japanese
phase 2 study
-- In May, NicOx announced that Merck & Co., Inc. initiated the first in a
series of planned clinical studies, in mild to moderate hypertensive
patients, under the companies' collaborative agreement to develop new
nitric oxide-donating antihypertensive agents using NicOx' proprietary
technology. Three drug candidates have now been selected from the
companies' joint research program, of which two have completed initial
dose ranging studies in healthy volunteers, under the exploratory
clinical study paradigm, with encouraging results.
Eric Castaldi, Chief Financial Officer of NicOx, declared: "In the first quarter of 2008, we have continued to focus our efforts on completing the clinical development of naproxcinod and taking the initial steps necessary for the product's planned commercialization. An important part of our clinical development strategy is to confirm that naproxcinod has no detrimental impact on blood pressure in patients with osteoarthritis and the two new ABPM studies are designed to further highlight this key potential differentiating factor. Going forward we will be seeking partnership agreements for naproxcinod and we aim to retain certain commercialization rights in the US and selected EU markets, in order to fully exploit the drug's commercial and strategic value and to aid NicOx' planned transition to a fully integrated pharmaceutical business.
As anticipated, we have seen our operating expenses increase
significantly during the first three months of 200
|SOURCE NicOx S.A.|
Copyright©2008 PR Newswire.
All rights reserved